Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

After doctors dismissed Rheanca's pain because they couldn't see where it hurt, she knew people with disability in regional ...

Rubbing the skin vigorously leaves a mark and sometimes complicates the injury, as in some dermatitis cases. Now scientists ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis ...

Academics at Chinese University of Hong Kong also say they have developed new probiotics for children and adults to target ...

Potent topical steroids outperform mild ones in treating moderate atopic dermatitis in children, improving symptom control and quality of life.

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...

Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes ...